Squarepoint’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-20,509
| Closed | -$30K | – | 3649 |
|
|
2022
Q2 | $30K | Buy |
+20,509
| New | +$15.1K | ﹤0.01% | 2753 |
|
|
2022
Q1 | – | Sell |
-100,416
| Closed | -$251K | – | 3824 |
|
|
2021
Q4 | $251K | Buy |
+100,416
| New | +$395K | ﹤0.01% | 2555 |
|
|
2021
Q1 | – | Sell |
-36,159
| Closed | -$393K | – | 3810 |
|
|
2020
Q4 | $393K | Sell |
36,159
-44,212
| -55% | -$545K | ﹤0.01% | 2003 |
|
|
2020
Q3 | $959K | Buy |
80,371
+8,314
| +12% | +$111K | 0.01% | 1022 |
|
|
2020
Q2 | $1.16M | Buy |
72,057
+57,348
| +390% | +$1M | 0.02% | 856 |
|
|
2020
Q1 | $228K | Buy |
+14,709
| New | +$316K | 0.01% | 1417 |
|
|
2019
Q2 | – | Sell |
-77,700
| Closed | -$963K | – | 2762 |
|
|
2019
Q1 | $963K | Buy |
77,700
+6,247
| +9% | +$69.8K | 0.01% | 1128 |
|
|
2018
Q4 | $440K | Buy |
71,453
+37,753
| +112% | +$288K | 0.01% | 1321 |
|
|
2018
Q3 | $357K | Buy |
33,700
+15,151
| +82% | +$173K | ﹤0.01% | 1462 |
|
|
2018
Q2 | $251K | Buy |
18,549
+4,497
| +32% | +$70K | ﹤0.01% | 1456 |
|
|
2018
Q1 | $249K | Buy |
+14,052
| New | +$237K | ﹤0.01% | 1401 |
|
|
2017
Q4 | – | Sell |
-25,902
| Closed | -$493K | – | 2415 |
|
|
2017
Q3 | $493K | Buy |
25,902
+12,479
| +93% | +$190K | 0.01% | 986 |
|
|
2017
Q2 | $203K | Buy |
+13,423
| New | +$203K | ﹤0.01% | 1302 |
|
|
2016
Q1 | – | Sell |
-10,300
| Closed | -$165K | – | 1529 |
|
|
2015
Q4 | $165K | Buy |
+10,300
| New | +$153K | 0.02% | 1053 |
|
Other funds holding EPZM
Squarepoint's EPZM Position: Q3 2022 in Review
Squarepoint sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 20,509 shares — an estimated $30K sold.
Squarepoint first reported a position in EPZM in Q4 2015 and held it in 14 quarters. The position peaked at $1.16M in Q2 2020. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Squarepoint reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Squarepoint sold 20,509 Epizyme, Inc shares in Q3 2022, an estimated $30K.
- Squarepoint first reported a position in Epizyme, Inc in Q4 2015 and held it in 14 quarters.
- Squarepoint's Epizyme, Inc position peaked at $1.16M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.